Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023.
The Maryland, US-based commercial cell-engineering company with an office in Cheshire, England will release its annual results next week Wednesday.
For the fourth quarter of 2022, MaxCyte anticipates growth of around 22% to about $12.4 million from $10.2 million. Meanwhile, for 2022 as a whole, it expects a 31% climb to $44.3 million from $33.9 million.
Further, for 2023, the company expects revenue growth between 21% and 26% and strategic platform license programme-related revenue of around $6 million, compared to around $4.6 million in 2022.
‘Our diverse and robust partnership portfolio continues to grow with three new partnerships added in 2022, in addition to the signing of a partnership with Vertex Pharmaceuticals following the transfer from CRISPR Therapeutics for the development of its CRISPR/Cas9-based gene-edited therapy,’ said Chief Executive Officer Doug Doerfler.
The company made no mention of profit or loss expectations. In 2021, it had a net loss of $19.1 million, widened 62% from $11.8 million in 2020.
MaxCyte shares were 5.0% lower at 370.50 pence each in London on Tuesday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.